Irene Karampela

Dr. Irene Karampela

Second Deparment of Critical Care, University General Hospital Attikon, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
GCGerasimos Socrates Christodoulatos
Gerasimos Socrates Christodoulatos
Irene KarampelaIrene Karampela
Irene Karampela
DTDimitrios Tsilingiris
Dimitrios Tsilingiris
FMFaidon Magkos
Faidon Magkos
MDMaria Dalamaga
Maria Dalamaga
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. NAFLD begins as a relatively benign hepatic steatosis which can evolve to non-alcoholic steatohepatitis (NASH); the risk of cirrhosis and hepatocellular carcinoma (HCC) increases when fibrosis is present. NAFLD represents a complex process implicating numerous factors—genetic, metabolic, and dietary—intertwined in a multi-hit etiopathogenetic model. Recent data have highlighted the role of gut dysbiosis, which may render the bowel more permeable, leading to increased free fatty acid absorption, bacterial migration, and a parallel release of toxic bacterial products, lipopolysaccharide (LPS), and proinflammatory cytokines that initiate and sustain inflammation. Although gut dysbiosis is present in each disease stage, there is currently no single microbial signature to distinguish or predict which patients will evolve from NAFLD to NASH and HCC. Using 16S rRNA sequencing, the majority of patients with NAFLD/NASH exhibit increased numbers of Bacteroidetes and differences in the presence of Firmicutes, resulting in a decreased F/B ratio in most studies. They also present an increased proportion of species belonging to Clostridium, Anaerobacter, Streptococcus, Escherichia, and Lactobacillus, whereas Oscillibacter, Flavonifaractor, Odoribacter, and Alistipes spp. are less prominent. In comparison to healthy controls, patients with NASH show a higher abundance of Proteobacteria, Enterobacteriaceae, and Escherichia spp., while Faecalibacterium prausnitzii and Akkermansia muciniphila are diminished. Children with NAFLD/NASH have a decreased proportion of Oscillospira spp. accompanied by an elevated proportion of Dorea, Blautia, Prevotella copri, and Ruminococcus spp. Gut microbiota composition may vary between population groups and different stages of NAFLD, making any conclusive or causative claims about gut microbiota profiles in NAFLD patients challenging. Moreover, various metabolites may be involved in the pathogenesis of NAFLD, such as short-chain fatty acids, lipopolysaccharide, bile acids, choline and trimethylamine-N-oxide, and ammonia. In this review, we summarize the role of the gut microbiome and metabolites in NAFLD pathogenesis, and we discuss potential preventive and therapeutic interventions related to the gut microbiome, such as the administration of probiotics, prebiotics, synbiotics, antibiotics, and bacteriophages, as well as the contribution of bariatric surgery and fecal microbiota transplantation in the therapeutic armamentarium against NAFLD. Larger and longer-term prospective studies, including well-defined cohorts as well as a multi-omics approach, are required to better identify the associations between the gut microbiome, microbial metabolites, and NAFLD occurrence and progression.

1 April 2021 in Current Obesity Reports
Verified
Journal Article
Closed access
PDF file
Irene KarampelaIrene Karampela
Irene Karampela
ASAlexandra Sakelliou
Alexandra Sakelliou
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
GCGerasimos Socrates Christodoulatos
Gerasimos Socrates Christodoulatos
FMFaidon Magkos
Faidon Magkos
MDMaria Dalamaga
Maria Dalamaga

Verified
Journal Article
Open access
PDF file
MDMaria Dalamaga
Maria Dalamaga
DKDimitris Kounatidis
Dimitris Kounatidis
DTDimitrios Tsilingiris
Dimitrios Tsilingiris
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
Irene KarampelaIrene Karampela
Irene Karampela
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou
Excess body weight constitutes one of the major health challenges for societies and healthcare systems worldwide. Besides the type of diet, calorie intake and the lack of physical exercise, recent data have highlighted a possible association between endocrine-disrupting chemicals (EDCs), such as bisphenol A, phthalates and their analogs, and obesity. EDCs represent a heterogeneous group of chemicals that may influence the hormonal regulation of body mass and adipose tissue morphology. Based on the available data from mechanistic, animal and epidemiological studies including meta-analyses, the weight of evidence points towards the contribution of EDCs to the development of obesity, associated disorders and obesity-related adipose tissue dysfunction by (1) impacting adipogenesis; (2) modulating epigenetic pathways during development, enhancing susceptibility to obesity; (3) influencing neuroendocrine signals responsible for appetite and satiety; (4) promoting a proinflammatory milieu in adipose tissue and inducing a state of chronic subclinical inflammation; (5) dysregulating gut microbiome and immune homeostasis; and (6) inducing dysfunction in thermogenic adipose tissue. Critical periods of exposure to obesogenic EDCs are the prenatal, neonatal, pubertal and reproductive periods. Interestingly, EDCs even at low doses may promote epigenetic transgenerational inheritance of adult obesity in subsequent generations. The aim of this review is to summarize the available evidence on the role of obesogenic EDCs, specifically BPA and phthalate plasticizers, in the development of obesity, taking into account in vitro, animal and epidemiologic studies; discuss mechanisms linking EDCs to obesity; analyze the effects of EDCs on obesity in critical chronic periods of exposure; and present interesting perspectives, challenges and preventive measures in this research area.

Verified
Journal Article
Open access
PDF file
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
DKDimitris Kounatidis
Dimitris Kounatidis
DTDimitrios Tsilingiris
Dimitrios Tsilingiris
FPFotis Panagopoulos
Fotis Panagopoulos
GCGerasimos Socrates Christodoulatos
Gerasimos Socrates Christodoulatos
MDMaria Dalamaga
Maria Dalamaga
Obesity and obesity-associated disorders pose a major public health issue worldwide. Apart from conventional weight loss drugs, next-generation probiotics (NGPs) seem to be very promising as potential preventive and therapeutic agents against obesity. Candidate NGPs such as Akkermansia muciniphila, Faecalibacterium prausnitzii, Anaerobutyricum hallii, Bacteroides uniformis, Bacteroides coprocola, Parabacteroides distasonis, Parabacteroides goldsteinii, Hafnia alvei, Odoribacter laneus and Christensenella minuta have shown promise in preclinical models of obesity and obesity-associated disorders. Proposed mechanisms include the modulation of gut flora and amelioration of intestinal dysbiosis, improvement of intestinal barrier function, reduction in chronic low-grade inflammation and modulation of gut peptide secretion. Akkermansia muciniphila and Hafnia alvei have already been administered in overweight/obese patients with encouraging results. However, safety issues and strict regulations should be constantly implemented and updated. In this review, we aim to explore (1) current knowledge regarding NGPs; (2) their utility in obesity and obesity-associated disorders; (3) their safety profile; and (4) their therapeutic potential in individuals with overweight/obesity. More large-scale, multicentric and longitudinal studies are mandatory to explore their preventive and therapeutic potential against obesity and its related disorders.

20 June 2020 in Current Obesity Reports
Verified
Journal Article
Closed access
PDF file
Irene KarampelaIrene Karampela
Irene Karampela
ECEvangelia Chrysanthopoulou
Evangelia Chrysanthopoulou
GCGerasimos Socrates Christodoulatos
Gerasimos Socrates Christodoulatos
MDMaria Dalamaga
Maria Dalamaga

4 May 2021 in Current Obesity Reports
Verified
Journal Article
Closed access
PDF file
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
MDMaria Dalamaga
Maria Dalamaga
TSTheodora Stratigou
Theodora Stratigou
Irene KarampelaIrene Karampela
Irene Karampela
Christina TsigalouChristina Tsigalou
Christina Tsigalou